Today, I stand at the crossroads of grief and hope.
The UK's approval of the world's first CRISPR–Cas9 gene editingtherapy, Casgevy, marks a milestone that resonates deeply with my family's journey. Having lost my son Ian to a rare kidney cancer linked to Sickle Cell Trait, this breakthrough in medical science is a beacon of light in the long, dark tunnel of genetic disorders.
As I've championed the importance of plasma donation and medical research, today I celebrate the tenacity of scientists at Vertex Pharmaceuticals and CRISPR Therapeutics. Their dedication has given birth to Casgevy, not just a therapy, but a promise of a future where no other parent watches their child suffer from conditions like sickle cell disease and transfusion-dependent β-thalassemia.
This moment is a testament to the unyielding spirit of families like mine and the relentless pursuit of hope and healing. Together, we are turning the page to a new chapter where the pain of the past fuels the breakthroughs of tomorrow. ?????
#CRISPRTherapy #BiotechBreakthrough #FamilyStrength #VertexPharmaceuticals #CRISPRTherapeutics #HopeInHealing
Owner, Partner, Founder, Collaborator.
1 年I can’t imagine this kind of loss my friend, thank you for sharing, and what an amazing step forward for those that have this effecting their lives.